Infinium Pharmachem Ltd
Incorporated in 2003, Infinium Pharmachem Ltd manufactures and sells Iodian based Pharmaceutical Intermediates[1]
- Market Cap ₹ 303 Cr.
- Current Price ₹ 218
- High / Low ₹ 316 / 95.0
- Stock P/E 33.2
- Book Value ₹ 38.2
- Dividend Yield 0.00 %
- ROCE 36.8 %
- ROE 53.4 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has a good return on equity (ROE) track record: 3 Years ROE 53.3%
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs
Half Yearly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|---|
| 36 | 55 | 74 | 101 | |
| 33 | 50 | 65 | 86 | |
| Operating Profit | 3 | 5 | 9 | 15 |
| OPM % | 7% | 9% | 12% | 15% |
| 1 | 1 | 1 | 1 | |
| Interest | 1 | 1 | 2 | 3 |
| Depreciation | 1 | 1 | 1 | 1 |
| Profit before tax | 1 | 4 | 7 | 12 |
| Tax % | 27% | 28% | 26% | 25% |
| 1 | 3 | 6 | 9 | |
| EPS in Rs | 5.10 | 13.60 | 27.50 | 8.97 |
| Dividend Payout % | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 41% |
| TTM: | 37% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 108% |
| TTM: | 66% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 114% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 53% |
| Last Year: | 53% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
|---|---|---|---|---|---|
| Equity Capital | 1 | 1 | 1 | 5 | 14 |
| Reserves | 3 | 6 | 12 | 17 | 39 |
| 9 | 11 | 23 | 26 | 0 | |
| 7 | 13 | 14 | 13 | 39 | |
| Total Liabilities | 21 | 31 | 49 | 60 | 92 |
| 4 | 4 | 4 | 16 | 16 | |
| CWIP | 0 | 4 | 8 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 |
| 16 | 22 | 37 | 44 | 76 | |
| Total Assets | 21 | 31 | 49 | 60 | 92 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|---|
| 2 | 7 | 9 | 7 | |
| -1 | -5 | -7 | -3 | |
| -1 | -1 | -2 | -3 | |
| Net Cash Flow | 0 | 1 | 0 | 2 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|---|
| Debtor Days | 75 | 70 | 64 | 55 |
| Inventory Days | 90 | 80 | 96 | 93 |
| Days Payable | 80 | 105 | 69 | 45 |
| Cash Conversion Cycle | 85 | 45 | 91 | 102 |
| Working Capital Days | 86 | 52 | 91 | 101 |
| ROCE % | 32% | 34% | 37% |
Business Overview:[1]
IPL is a GMP compliant, FDA Approved and ISO 9001-2015 certified coimpany which does development, manufacture, and export of Iodine Derivatives & API. Currently, it has 250+ intermediates and 15+ APIs. It supplies a range of Iodine derivatives on Order to Made basis